Advanced 64Cu/67Cu-Based Theranostics: Application of the Copper Chelator TE1PA to a Murine Model of HER2-Positive Gastric Cancer

Le résumé fourni par la source

The development of 64 Cu/ 67 Cu-based theranostic probes addresses the need for integrated cancer diagnosis and therapy. To target HER2-positive gastric cancer, trastuzumab was conjugated to p -SCN-Bn-TE1PA (DOL of 1.1–2.0), achieving high yields and purity. Binding assays on BT-474 cells confirmed the preserved cellular uptake of the bioconjugate. The successful radiolabeling of Trastuzumab- p -SCN-Bn-TE1PA (DOL of 2) with both the 64 Cu- and 67 Cu-isotopes demonstrated suitability for in vivo studies. In a preclinical model of HER2-positive gastric cancer, [ 64 Cu]Cu- Trastuzumab- p -SCN-Bn-TE1PA enabled effective PET imaging with tumor-specific uptake (>21%IA/g) and clearance through the spleen, liver and kidneys. Therapeutic studies with [ 67 Cu]Cu- Trastuzumab- p -SCN-BnTE1PA (10–20 MBq) demonstrated dose-dependent tumor inhibition of growth, without toxicity or adverse health effects. This work exemplifies the clinical potential of associating 64 Cu-imaging and 67 Cu-therapy. By combining a robust isotopic pair, a customized bifunctional chelator and trastuzumab, this study demonstrates a promising approach for HER2-positive gastric cancer treatment in nuclear medicine, paving the way for personalized copper-based theranostics.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.